Orasure Technologies Inc  (OSUR)
Other Ticker:  
Price: $4.9200 $-0.13 -2.574%
Day's High: $5.0699 Week Perf: 0.00
Day's Low: $ 4.84 30 Day Perf: -10.55 %
Volume (M): 782 52 Wk High: $ 8.45
Volume (M$): $ 3,846 52 Wk Avg: $6.19
Open: $5.06 52 Wk Low: $4.38

 Market Capitalization (Millions $) 364
 Shares Outstanding (Millions) 74
 Employees 450
 Revenues (TTM) (Millions $) 304
 Net Income (TTM) (Millions $) 23
 Cash Flow (TTM) (Millions $) 157
 Capital Exp. (TTM) (Millions $) 6

Orasure Technologies Inc
Orasure Technologies Inc. is a public health diagnostic company that specializes in the development, manufacture, and distribution of oral fluid collection devices, diagnostic kits, and platform technologies. The company, which is headquartered in Bethlehem, Pennsylvania, was founded in 2000, and it primarily focuses on developing innovative medical solutions for HIV, hepatitis C, and other infectious diseases.

Orasure Technologies has developed a range of products that are marketed in more than 100 countries worldwide. Its flagship product is the OraQuick HIV, which is the first FDA-approved and CLIA waived rapid oral fluid test for HIV-1 and HIV-2. OraQuick is very easy to use, and it provides accurate results within 20 minutes, making it an important tool for public health screening programs.

In addition to OraQuick, Orasure Technologies has developed a portfolio of other health diagnostic products. These include OraSure, an oral specimen collection device used for testing hepatitis C; Intercept, a collection device used for oral fluid drug screening; and GenoSure PRIME, a genetic sequencing test used for HIV viral load monitoring.

One of the significant achievements of Orasure Technologies is its collaboration with the Centers for Disease Control and Prevention (CDC) to develop the first at-home HIV testing kit named "OraQuick In-Home HIV Test." The kit is marketed directly to the general public and provides an accessible home testing option, helping people control their HIV status and make informed decisions about their health.

Orasure Technologies has been recognized for its innovative technologies and outstanding business practices. It has been awarded numerous patents for its products and has been listed among the top 25 innovative companies by the Technology Fast 500 list in 2015.

In summary, Orasure Technologies Inc is a global industry leader in the public health diagnostic field, with products that are making a tremendous impact on combating the spread of infectious diseases such as HIV and hepatitis. The company has demonstrated a commitment to innovation and its corporate values of reliability, innovation, and excellence in serving its customers.

   Company Address: 220 East First Street Bethlehem 18015 PA
   Company Phone Number: 882-1820   Stock Exchange / Ticker: NASDAQ OSUR


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Orasure Technologies Inc

Orasure Technologies Inc Faces Financial Setback in First Quarter of 2024

In the first quarter of 2024, Orasure Technologies Inc faced a challenging financial period, with the company slipping into a deficit of $-0.05 per share compared to $0.37 in the same quarter a year before. Additionally, Income per Share fell from $0.26 to $0.05 from the preceding quarter. The sharp drop in revenue by -65.111% to $54.07 million from $154.96 million in the comparable quarter a year before was certainly a cause for concern. Sequentially, revenue fell by -28.841% from $75.98 million.
It is important to note that the rest of the Medical Equipment & Supplies sector recorded a top-line improvement in the first quarter of 2024, indicating that the challenges faced by Orasure Technologies Inc may not be industry-wide, but rather specific to the company itself.

Management Changes

NOWDiagnostics Appoints Dr. Stephen S. Tang as Chairman of the Board, Bolstering Industry Expertise and Driving Innovation in Diagnostic Healthcare

Published Thu, Mar 21 2024 12:31 PM UTC

NOWDiagnostics, a leading developer of over-the-counter (OTC) and point-of-care (POC) diagnostic tests, has recently named Dr. Stephen S. Tang as the chairman of the company's board of directors. Dr. Tang brings a wealth of experience and industry expertise to the table, having been a longstanding veteran of the medical diagnostic industry.
Prior to joining NOW...

Orasure Technologies Inc

Contrasting Financial Performance: Strong EPS Growth Amidst Declining Revenue for Orasure Technologies Inc.

/>Orasure Technologies Inc. (NASDAQ: OSUR) recently released its financial results for the fourth quarter of 2023, showcasing a 22.04% increase in income growth. Despite this positive trajectory, the company also experienced a significant decline in revenue. This article will analyze the key financial figures and provide an overview of the company's performance during the period.
Financial Results:
1. Income Growth: OSUR reported a commendable 22.04% growth in income, reaching $0.26 per share in Q4 2023, compared to $0.15 per share in the previous reporting season. This represents a substantial increase of 72.71% in earnings per share year-on-year.

Orasure Technologies Inc

OSUR Makes a Stunning Surge with Profits Soaring by 114.29% in Q3 of 2023

Orasure Technologies Inc Reports Astonishing Income Elevation in Q3 2023
Bethlehem, PA - Orasure Technologies Inc (NASDAQ: OSUR) has recently announced impressive financial results for the third quarter of 2023, showcasing a significant increase in income and positive developments despite a decline in revenue. The medical equipment and supplies industry as a whole also experienced top-line growth during this period, painting a promising picture for the sector.
During the financial interval ending September 30, 2023, Orasure Technologies Inc reported an astonishing income elevation of 114.29%, with earnings per share reaching $0.15. Although the company saw fading revenue of -24.148% amounting to $88.34 million relative to the preceding year, the positive growth in income is a positive indicator for investors.

Orasure Technologies Inc

Orasure Technologies Inc Reports Reduced EPS of $-0.07, Yet Outperforms Industry Revenue Growth in Q2 2023

Date: August 2, 2023
Orasure Technologies Inc, a leading player in the Medical Equipment & Supplies industry, recently announced its financial results for the fiscal second quarter of 2023. While the company reported revenue growth and a decrease in losses, some concerns remain regarding its future performance.
In the second quarter of 2023, Orasure Technologies Inc (OSUR) posted a loss of $0.07 per share, an improvement from the $0.26 loss per share in the same period last year. Additionally, the company's earnings per share (EPS) fell from $0.37 in the previous financial reporting period. Although this decline is noteworthy, it is important to consider the surge in revenue.


Orasure Technologies Inc's Segments
• View Complete Report
  Company Estimates  
  Revenue Outlook
Orasure Technologies Inc does not provide revenue guidance.

Earnings Outlook
Orasure Technologies Inc does not provide earnings estimates.

Geographic Revenue Dispersion


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com